Bemegride (also marketed as Megimide) is a central nervous system stimulant and antidote for barbiturate poisoning as its chemoreceptor agonism increases mean tidal volume, thereby increasing respiration and the concentration of O2 in blood although it may be theoretically used as a supportive measure in treating any depressant overdose.
Mepixanox
Mepixanox (Pimexone) is a respiratory stimulant.
Dimefline
Dimefline is a respiratory stimulant.
Pentylenetetrazol
Pentylenetetrazol, also known as pentylenetetrazole, metrazol, pentetrazol (INN), pentamethylenetetrazol, Corazol, Cardiazol or PTZ, is a drug formerly used as a circulatory and respiratory stimulant.
CX-546
CX-546 is an ampakine drug developed by Cortex Pharmaceuticals.
Almitrine
Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC.
Budesonide/formoterol
Budesonide/formoterol is a combination formulation containing budesonide and formoterol used in the management of asthma and chronic obstructive pulmonary disease (COPD).
Etamivan
Etamivan (INN, or ethamivan (USAN); trade names Analepticon and Vandid) is a respiratory stimulant drug related to nikethamide.
GAL-021
GAL-021 is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel, although secondary mechanisms may also be involved.
BW373U86
(+)-BW373U86 is an opioid analgesic drug used in scientific research.
BIMU8
BIMU-8 is a drug which acts as a 5-HT4 receptor selective agonist.
Zacopride
Zacopride is a potent antagonist at the 5-HT3 receptor and an agonist at the 5-HT4 receptor.
Leptacline
Leptacline (INN) (developmental code name SD 210-32) is a drug described as a respiratory stimulant that was never marketed.
Amiphenazole
Amiphenazole (Daptazile) is a respiratory stimulant traditionally used as an antidote for barbiturate or opiate overdose, usually in combination with bemegride, as well as poisoning from other sedative drugs and treatment of respiratory failure from other causes.
AZD5423
AZD5423 is a nonsteroidal glucocorticoid and phase II drug by AstraZeneca disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.
Nikethamide
Nikethamide is a stimulant which mainly affects the respiratory cycle.
Doxapram
Doxapram hydrochloride (marketed as Dopram, Stimulex or Respiram) is a respiratory stimulant.